Experimental pancreatic cancer drug offers new hope in major trial

Experimental pill offers breakthrough hope in pancreatic cancer fight

Daraxonrasib, a daily oral KRAS inhibitor by Revolution Medicines, nearly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.7 months) in a 500-patient Phase 3 trial, with the FDA fast-tracking review. The drug breaks a decades-long stalemate on KRAS — mutated in 90%+ of pancreatic cases — signaling that the "undruggable" oncology target class is now open, with downstream implications for RAS-driven cancers beyond pancreatic.